Literature DB >> 21775882

Cancer trials versus the real world in the United States.

Waddah B Al-Refaie1, Selwyn M Vickers, Wei Zhong, Helen Parsons, David Rothenberger, Elizabeth B Habermann.   

Abstract

BACKGROUND: Federal policies have been implemented to mitigate underenrollment in cancer trials in the United States. We sought to identify patterns and predictors of enrollment patterns to cancer trials in a contemporary era using a real world setting. STUDY
DESIGN: The 2001-2008 California Cancer Registry was used to determine patterns and predictors of enrollment in clinical trials for stage 0 to IV solid organ malignant tumors. Multivariate techniques were used to identify predictors of enrollment in cancer protocols, controlling for covariates.
RESULTS: Less than a percent (0.64%) of patients enrolled in clinical trials (1566 of 244,528). Black patients were less likely than whites to enroll in trials (0.48% vs 0.67%, P < 0.05). On multivariate analysis, older persons (>65 years), early stage cancer, and those with lung or gastrointestinal cancers were less likely to be enrolled in cancer trials. Results were consistent when evaluated among only nonbreast cancer protocols. Though approaching significance, black, underinsured, and uninsured patients showed trends toward underenrollment.
CONCLUSION: In addition to profoundly low overall cancer trial accrual, vast underrepresentation by age, cancer stage, and site continue to exist. The generalizability of these trials to a real world perspective remains an open question. Physicians, payers, the National Cancer Institute, and other stakeholders need to develop broader cancer trials to benefit the millions of patients with cancer in the United States.

Entities:  

Mesh:

Year:  2011        PMID: 21775882     DOI: 10.1097/SLA.0b013e31822a7047

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  35 in total

1.  Does enrollment in cancer trials improve survival?

Authors:  Christopher J Chow; Elizabeth B Habermann; Anasooya Abraham; Yanrong Zhu; Selwyn M Vickers; David A Rothenberger; Waddah B Al-Refaie
Journal:  J Am Coll Surg       Date:  2013-02-13       Impact factor: 6.113

2.  Health policy: Overcoming cost barriers to clinical trial participation.

Authors:  Neal J Meropol
Journal:  Nat Rev Clin Oncol       Date:  2016-05-20       Impact factor: 66.675

Review 3.  Contemporary use of real-world data for clinical trial conduct in the United States: a scoping review.

Authors:  James R Rogers; Junghwan Lee; Ziheng Zhou; Ying Kuen Cheung; George Hripcsak; Chunhua Weng
Journal:  J Am Med Inform Assoc       Date:  2021-01-15       Impact factor: 4.497

4.  The Role of Oncology Nurses in Discussing Clinical Trials.

Authors:  Susan A Flocke; Elizabeth Antognoli; Barbara J Daly; Brigid Jackson; Sarah E Fulton; Tasnuva M Liu; Jessica Surdam; Sharon Manne; Neal J Meropol
Journal:  Oncol Nurs Forum       Date:  2017-09-01       Impact factor: 2.172

5.  Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With Cancer.

Authors:  Lauren M Hamel; Louis A Penner; Terrance L Albrecht; Elisabeth Heath; Clement K Gwede; Susan Eggly
Journal:  Cancer Control       Date:  2016-10       Impact factor: 3.302

6.  Application of best practice approaches for designing decision support tools: the preparatory education about clinical trials (PRE-ACT) study.

Authors:  Linda Fleisher; Dominique G Ruggieri; Suzanne M Miller; Sharon Manne; Terrance Albrecht; Joanne Buzaglo; Michael A Collins; Michael Katz; Tyler G Kinzy; Tasnuva Liu; Cheri Manning; Ellen Specker Charap; Jennifer Millard; Dawn M Miller; David Poole; Stephanie Raivitch; Nancy Roach; Eric A Ross; Neal J Meropol
Journal:  Patient Educ Couns       Date:  2014-04-21

7.  Impact of primary care provider knowledge, attitudes, and beliefs about cancer clinical trials: implications for referral, education and advocacy.

Authors:  Margo Michaels; Thomas A D'Agostino; Natasha Blakeney; Elisa S Weiss; Maria C Binz-Scharf; Mitch Golant; Carma L Bylund
Journal:  J Cancer Educ       Date:  2015-03       Impact factor: 2.037

8.  Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriers.

Authors:  S Manne; D Kashy; T Albrecht; Y-N Wong; A Lederman Flamm; A B Benson; S M Miller; Linda Fleisher; J Buzaglo; N Roach; M Katz; E Ross; M Collins; D Poole; S Raivitch; D M Miller; T G Kinzy; T Liu; N J Meropol
Journal:  Eur J Cancer Care (Engl)       Date:  2014-01-28       Impact factor: 2.520

9.  Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study.

Authors:  Daniel A Barocas; Vivien Chen; Matthew Cooperberg; Michael Goodman; John J Graff; Sheldon Greenfield; Ann Hamilton; Karen Hoffman; Sherrie Kaplan; Tatsuki Koyama; Alicia Morgans; Lisa E Paddock; Sharon Phillips; Matthew J Resnick; Antoinette Stroup; Xiao-Cheng Wu; David F Penson
Journal:  J Comp Eff Res       Date:  2013-07       Impact factor: 1.744

10.  Educating low-SES and LEP survivors about breast cancer research: pilot test of the Health Research Engagement Intervention.

Authors:  Alyssa Nickell; Nancy J Burke; Elly Cohen; Maria Caprio; Galen Joseph
Journal:  J Cancer Educ       Date:  2014-12       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.